Moscatilin, a potential therapeutic agent for cancer treatment: insights into molecular mechanisms and clinical prospects
Medical Oncology · 2024
DOI: 10.1007/s12032-024-02467-6 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Oncology, 2024. Verfasst von Rita Silva-Reis und 6 weiteren Autor:innen. Beteiligte Einrichtung: LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193, Aveiro, Portugal. Hauptthemen laut MEDLINE: Neoplasms, Bibenzyls. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 76 Literaturangaben.
Abstract (Originalsprache)
Moscatilin, a bibenzyl derivative from the Dendrobium genus, has been traditionally used in Chinese medicine. Recent studies suggest its potential as a powerful anticancer agent due to its diverse pharmacological properties.This review aims to consolidate current research on moscatilin's anticancer mechanisms, structure-activity relationships, and therapeutic potential to assess its viability for clinical use. A literature search was performed in PubMed/MedLine, Scopus, and Web of Science.The search focused on "cancer," "moscatilin," "anticancer," "bioactivity," "dendrobium," and "pharmacological properties." Relevant studies on molecular mechanisms, preclinical and clinical efficacy, and bioavailability were reviewed. Moscatilin exhibits significant anticancer effects in lung, breast, colorectal, and pancreatic cancers. It induces apoptosis via the JNK/SAPK pathway, inhibits cell proliferation, and suppresses metastasis. Structure-activity relationship studies reveal that phenolic groups and a two-carbon bridge are crucial for its efficacy. Additionally, moscatilin shows good bioavailability and a favorable safety profile, with low toxicity to healthy cells. Moscatilin demonstrates considerable potential as an anticancer agent, targeting multiple cancer progression pathways. Further clinical trials are essential to confirm its therapeutic efficacy and safety in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193, Aveiro, Portugal.
- CITAB Inov4Agro - Institute for Innovation, Capacity Building and Sustainability of Agri-food Production, University of Trás-os-Montes and Alto Douro (UTAD), 5000-801, Vila Real, Portugal.
- Department of Advanced Material Technologies, Faculty of Chemistry, Wrocław University of Science and Technology, Smoluchowskiego 25, Wroclaw, Poland.
- Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków Branch, Garncarska 11, Kraków, Poland.
- Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349, Craiova, Romania. calinadaniela@gmail.com.
- Department of Medicine, College of Medicine, Korea University, Seoul, 02841, Republic of Korea. javad.sharifirad@gmail.com.
Zitieren
APA
Silva-Reis, R., Silva, V. L. M., Cardoso, S. M., Michalak, I., Püsküllüoğlu, M., Calina, D., & Sharifi-Rad, J. (2024). Moscatilin, a potential therapeutic agent for cancer treatment: insights into molecular mechanisms and clinical prospects. Medical Oncology. https://doi.org/10.1007/s12032-024-02467-6
Vancouver
Silva-Reis R, Silva VLM, Cardoso SM, Michalak I, Püsküllüoğlu M, Calina D, et al. Moscatilin, a potential therapeutic agent for cancer treatment: insights into molecular mechanisms and clinical prospects. Medical Oncology. 2024. doi:10.1007/s12032-024-02467-6
BibTeX
@article{SilvaReis2024,
author = {Silva-Reis, Rita and Silva, Vera L M and Cardoso, Susana M and Michalak, Izabela and Püsküllüoğlu, Mirosława and Calina, Daniela and Sharifi-Rad, Javad},
title = {Moscatilin, a potential therapeutic agent for cancer treatment: insights into molecular mechanisms and clinical prospects},
journal = {Medical Oncology},
year = {2024},
doi = {10.1007/s12032-024-02467-6}
}
EUVIMED